ASRS 2019 Street Team: Peter K. Kaiser, MD

August 26, 2019
OT Staff Reports

Dr. Kaiser discusses how risuteganib fared in a phase II trial in patients with intermediate nonexudative AMD. 

Peter K. Kaiser, MD, shares the take-home message of his presentation, "Safety and Efficacy of Risuteganib in Intermediate Nonexudative Age-Related Macular Degeneration: First Time Results From a Phase 2 Study." Dr. Kaiser presented at the 2019 annual meeting of the American Society of Retina Specialists.

Related Content:

ASRS | Retina